Journals / JAREM / 2019 / Cilt: 9 - Sayı: 2

Examination of CFTR Gene Mutations in Patient Groups with Borderline Sweat Test and Clinical Preliminary Diagnosis of Cystic Fibrosis by Next-Generation Sequencing Method in Şanlıurfa Province

Şanlıurfa İlindeki Ter Testi Sonucu Şüpheli Olan ve Klinik Ön Tanısı Kistik Fibrozis Olan Hasta Gruplarındaki CFTR Gen Mutasyonlarının Yeni Nesil Dizileme Yöntemi ile İncelenmesi

Journal
JAREM
Pages
86–90
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our research concludes that the sweat test is more important than clinical suspicion, and every patient with borderline sweat test should be immediately investigated.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Cystic fibrosis (CF) is the most common autosomal recessive mortal disease in the Caucasians.
📊
Key Findings & Data:Its prevalence is 1/2500-3300, and its carrier frequency is 1/20-25.
💡
Conclusion & Impact:Conclusion: Our research concludes that the sweat test is more important than clinical suspicion, and every patient with borderline sweat test should be immediately investigated.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Cystic fibrosis (CF) is the most common autosomal recessive mortal disease in the Caucasians. Its prevalence is 1/2500-3300, and its carrier frequency is 1/20-25. A mutation at the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is also known as chlorine permeable transmembrane channel, results in CF. There is a difference in the distribution of patients between patient groups and regions. This paper aimed to investigate the mutation dispersion in the state of Sanliurfa in patients who have borderline sweat test results or a clinic suspicion of CF. Methods: A total of 40 patients with borderline sweat test results (first group) and 62 patients with clinically suspected CF (second group) were investigated by next-generation sequencing for CFTR gene mutations. Results: In the first group, 11 heterozygous (27.5%), 1 compound heterozygous (2.5%), and 28 homozygous (70%) mutations were determined. In the second group, 16 heterozygous (25.8%), 3 compound heterozygous (4.8%), and 13 homozygous (21%) mutations were determined. The most frequent mutations were I148T and ΔF508. Conclusion: Our research concludes that the sweat test is more important than clinical suspicion, and every patient with borderline sweat test should be immediately investigated.

Özet

Amaç: Kistik Fibrozis (KF) günümüzde 1/20-25 taşıyıcı frekansı ve 1/2500-3300 görülme oranı ile, beyaz ırktaki otozomal resif geçiş gösteren ölümcül hastalıklar içerisinde ilk sırada yer almaktadır. KF, klor geçirgen transmembran kanal olarak da bilinen kistik fibrozis transmembran regülatör (CFTR) geninde meydana gelen mutasyonlar sonucu açığa çıkmaktadır. Mutasyonların dağılım oranları hasta grupları arasında ve bölgesel olarak farlılık göstermektedir. Bu çalışmada Şanlıurfa ilinde ter testi şüpheli olan ve klinik ön tanısı KF olan bireyler mutasyon dağılımları açısından incelenmiştir. Yöntemler: Ter testi sonucu şüpheli olan 40 hasta ve klinik ön tanısı KF olan 62 hasta yeni nesil sekanslama yöntemi ile CFTR gen mutasyonları açısından değerlendirilmiştir. Bulgular: 40 bireyin yer aldığı ter testi sonucu şüpheli olan hasta grubunda; 11 birey heterozigot (%27,5), 1 birey compound-heterozigot (%2,5) ve 28 birey de homozigot (%70) mutasyona sahip olarak değerlendirildi. 62 bireyin yer aldığı klnik ön tanısı KF olan grupta; 16 birey heterozigot (%25,8), 3 birey compound heterozigot (%4,8) ve 13 birey homozigot (%21) mutasyona sahip olarak değerlendirildi. En sık gözlenen mutasyonlar ise I148T ve ΔF508 olarak bulundu. Sonuç: Çalışmamız hem ter testinin tanısal değerinin klinik değerlendirmeden daha önemli olduğunu hem de ter testi sonucu şüpheli olan bireylerin zaman kaybetmeden araştırılması gerektiğini göstermektedir.

🔖

Cite This Article

GÜMÜŞ, E. (2019). Examination of CFTR Gene Mutations in Patient Groups with Borderline Sweat Test and Clinical Preliminary Diagnosis of Cystic Fibrosis by Next-Generation Sequencing Method in Şanlıurfa Province. JAREM, Cilt: 9 - Sayı: 2, 86–90. https://ajindex.com/articles/178283

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Elborn JS. Cystic fibrosis. Lancet 2016; 388: 2519-31.
  2. Tug E, Tug T. Kistik Fibrozis ve Moleküler-Genetik Yaklasımlar. Toraks Derg 2003; 4: 198-204.
  3. Öztürk ÖG, Kibar F, Karaçor EDZ, Çetiner S, Şahin G, Yaman A. Adana İlinde CFTR Gen Mutasyonlarının Değerlendirilmesi. Cukurova Med J 2014; 38: 202-8.
  4. Oskoui M, Gazzellone MJ, Thiruvahindrapuram B, Zarrei M, Andersen J, Wei J, et al. Clinically relevant copy number variations detected in cerebral palsy. Nat Commun 2015; 6: 7949. Richards CS, Bradley LA, Amos J, Allitto B, Grody WW, Maddalena A, et al. Standards and Guidelines for CFTR Mutation Testing. Genet Med 2002; 4: 379-91.
  5. Zielenski J, Rozmahel R, Bozon D, Kerem BS, Grzelczak Z, Riordan JR, et al. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991; 10: 214-28.
  6. Wilschanski M, Zielenski J, Markiewicz D, Tsui LC, Corey M, Levison H, et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr 1995; 127: 705-10.
  7. Boyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med 2013; 1: 158-63.
  8. Üstü Y, Uğurlu M. Ulusal Erken Tanı ve Tarama Programı: Kistik Fibrozis National Early Diagnosis and Screening Program: Cystic Fibrosis. Ankara Med J 2016; 16: 239-41.
  9. McCloskey M, Redmond AOB, Hill A, Elborn JS. Clinical Features Associated with a Delayed Diagnosis of Cystic Fibrosis. Respiration 2000; 67: 402-7.
  10. Lucarelli M, Porcaro L, Biffignandi A, Costantino L, Giannone V, Alberti L, et al. A New Targeted CFTR Mutation Panel Based on NextGeneration Sequencing Technology. J Mol Diagn 2017; 19: 788-800.
  11. Loukas YL, Thodi G, Molou E, Georgiou V, Dotsikas Y, Schulpis KH. Clinical diagnostic Next-Generation sequencing: The case of CFTR carrier screening. Scand J Clin Lab Invest 2015; 75: 374-81.
  12. Lao O, Andrés AM, Mateu E, Bertranpetit J, Calafell F. Spatial patterns of cystic fibrosis mutation spectra in European populations. Eur J Hum Genet 2003; 11: 385-94.
  13. Kilinç MO, Ninis VN, Dağli E, Demirkol M, Ozkinay F, Arikan Z, et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. Am J Med Genet 2002; 113: 250-7.
  14. Burgel PR, Bellis G, Olesen HV, Viviani L, Zolin A, Blasi F, et al. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J 2015; 46: 133-41.
  15. Gokdemir Y, Erdem E, Akpınar